NUVA - ニュ―ベイシブ (NuVasive Inc.) ニュ―ベイシブ

 NUVAのチャート


 NUVAの企業情報

symbol NUVA
会社名 Nuvasive Inc (ニュ―ベイシブ)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 ニュベーシブ(NuVasive Inc)は医療機器会社である。同社は、最小限の破壊的外科用製品の開発と、背骨手術のための手続き型統合ソリューションの開発に集中する。同社の製品ポートフォリオは、脊椎固定術を補助するために使用される生物製剤を含む脊椎固定手術のアプリケーションに重点を置く。主力製品には、最大アクセス外科手術(MAS)と呼ばれる最小限の破壊的手術プラットフォームが含まれる。このプラットフォームには、NVM5を含むソフトウェア駆動の神経検出および回避システム、術中モニタリングサービスおよびサポート、統合スプリットブレードレトラクタシステムであるMaXcess、及び各種インプラント、バイオロジックが含まれる。このプラットフォームは、MaXcessリトラクタ、特殊インプラントおよび固定製品、外科医が神経を検出してナビゲートすることを総合的に可能にするインプラント送達のためのスパインへのカスタマイズされたアクセスを指示する3つの製品カテゴリを組み合わせている。   ニュ―ベイシブは米国の医療機器メ―カ―。整形外科領域の脊椎外科向けインプラント、神経モニタ―リング機器などの開発、製造、リ―ス、修理、設置・取り付け、調査研究、販売を行う。米国以外の拠点はプエルトリコ、英国、ドイツ、オ―ストラリア、シンガポ―ル、日本など。本社はカリフォルニア州。   NuVasive, Inc. engages in the development of minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. It offers cervical and spine fusion surgery, cervical plating, and posterior fixation products. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.
本社所在地 7475 Lusk Boulevard San Diego CA 92121 USA
代表者氏名 Gregory T. Lucier グレゴリー・T・ルシエ
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 858-909-1800
設立年月日 35612
市場名 NASDAQ National Market System
ipoyear 2004年
従業員数 2600人
url www.nuvasive.com
nasdaq_url https://www.nasdaq.com/symbol/nuva
adr_tso
EBITDA EBITDA(百万ドル) 238.77000
終値(lastsale) 69.67
時価総額(marketcap) 3582601952.16
時価総額 時価総額(百万ドル) 3190.763
売上高 売上高(百万ドル) 161.169
企業価値(EV) 企業価値(EV)(百万ドル) 3750.266
当期純利益 当期純利益(百万ドル) 22.43600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 NuVasive Inc. revenues increased 7% to $542.1M. Net loss totaled $15.6M vs. income of $24.6M. Revenues reflect International (excludes Puerto Rico) segment increase of 29% to $101.8M United States segment increase of 3% to $440.3M. Net loss reflects Litigation liability (gain) loss increase from $0K to $27.8M (expense) Sales Marketing increase of 7% to $283M (expense).

 NUVAのテクニカル分析


 NUVAのニュース

   NuVasive to Participate as Gold Level Sponsor at SMISS Annual Forum  2020/10/27 12:33:00 PR Newswire
SAN DIEGO, Oct. 27, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will participate as a gold level sponsor at the Society…
   Spine Allografts Market 2020 Key Country Analysis: Exactech, Inc., Lattice Biologics Ltd, Medtronic, NuTech Spine, Inc., NuVasive, Inc., RTI Surgical Holdings, Inc  2020/10/22 19:00:24 OpenPR
Spinal Allografts Market survey offers key information about the industry, helpful and important facts and figures, expert opinions, and the latest developments across the world. The Spinal Allografts Market report includes data on patterns and improvements, target business sectors and
   NuVasive (NASDAQ:NUVA) Research Coverage Started at Stifel Nicolaus  2020/10/22 10:06:48 Transcript Daily
Stifel Nicolaus started coverage on shares of NuVasive (NASDAQ:NUVA) in a report published on Monday morning, AR Network reports. The brokerage issued a buy rating and a $64.00 price target on the medical device company’s stock. A number of other equities research analysts also recently issued reports on NUVA. Credit Suisse Group reissued a buy […]
   MORGAN STANLEY: Buy these 61 stocks that will offer major earnings-driven upside following an imminent 10% market sell-off  2020/10/21 15:57:10 Business Insider
Summary List Placement When it comes to his outlook on the market for the next few months, Morgan Stanley's Mike Wilson is pessimistic. The bank's chief US equity strategist and chief investment officer said in a Monday note that he expects the market to drop another 10% in the near term as investors face uncertainty around the election outcome, more fiscal stimulus, and another wave of COVID-19. But once the dust settles, Wilson said he expects the bull market to ensue — one which will be led by cyclical and smaller-cap stocks as earnings get a boost from the economic recovery. As such, Wilson recommended using a near term sell-off as a buying opportunity. "We think the best opportunities lie in stocks where earnings are growing with the cyclical rebound and growing by enough to offset any valuation headwinds," Wilson said. He continued: "On any pullbacks, we would look to our earnings upside screen from September — 66% of stocks have outperformed the market with median outperformance of 2.
   Stifel Nicolaus Initiates Coverage on NuVasive (NASDAQ:NUVA)  2020/10/21 06:36:47 Dakota Financial News
Stifel Nicolaus initiated coverage on shares of NuVasive (NASDAQ:NUVA) in a research report issued to clients and investors on Monday, AnalystRatings.net reports. The brokerage set a “buy” rating and a $64.00 price target on the medical device company’s stock. Stifel Nicolaus’ price target would indicate a potential upside of 22.07% from the company’s current price. […]
   Analysts Estimate NuVasive (NUVA) to Report a Decline in Earnings: What to Look Out for  2020/04/29 16:34:36 Zacks Investment Research
NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   NuVasive (NUVA) Posts Q1 Preliminary Results, Withdraws View  2020/04/16 07:36:00 Zacks Investment Research
A decline in elective surgical procedures due to coronavirus outbreak weighs on NuVasive's (NUVA) preliminary revenue results for first-quarter 2020.
   US Intraoperative Neuromonitoring Market Analysis 2020-2024, Featuring Cadwell Industries, Medtronic Plc and NuVasive Inc. - ResearchAndMarkets.com  2020/03/24 12:40:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Intraoperative Neuromonitoring Market in the US 2020-2024" report has been added to ResearchAndMarkets.com's offering. The intraoperative neuromonitoring market (IONM) in the US is poised to grow by USD 955.33 mn during 2020-2024, progressing at a CAGR of 10% during the forecast period. This report provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers
   Here's Why You Should Hold on to NuVasive (NUVA) Stocks Now  2020/03/23 15:24:00 Zacks Investment Research
Investors continue to be optimistic about NuVasive (NUVA) on its strong segmental and international results in the fourth quarter of 2019.
   NuVasive, Inc. Announces Pricing Of Offering Of $450 Million Of 0.375% Convertible Senior Notes Due 2025  2020/02/27 07:11:00 PR Newswire
SAN DIEGO, Feb. 26, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA) announced today the pricing of its offering of $450,000,000 aggregate principal amount of 0.375% Convertible Senior Notes due 2025 (the "Convertible Notes") in a private placement to qualified institutional buyers…
   US Intraoperative Neuromonitoring Market Analysis 2020-2024, Featuring Cadwell Industries, Medtronic Plc and NuVasive Inc. - ResearchAndMarkets.com  2020/03/24 12:40:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Intraoperative Neuromonitoring Market in the US 2020-2024" report has been added to ResearchAndMarkets.com's offering. The intraoperative neuromonitoring market (IONM) in the US is poised to grow by USD 955.33 mn during 2020-2024, progressing at a CAGR of 10% during the forecast period. This report provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers
   Here's Why You Should Hold on to NuVasive (NUVA) Stocks Now  2020/03/23 15:24:00 Zacks Investment Research
Investors continue to be optimistic about NuVasive (NUVA) on its strong segmental and international results in the fourth quarter of 2019.
   NuVasive, Inc. Announces Pricing Of Offering Of $450 Million Of 0.375% Convertible Senior Notes Due 2025  2020/02/27 07:11:00 PR Newswire
SAN DIEGO, Feb. 26, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA) announced today the pricing of its offering of $450,000,000 aggregate principal amount of 0.375% Convertible Senior Notes due 2025 (the "Convertible Notes") in a private placement to qualified institutional buyers…
   NuVasive, Inc. Announces Proposed Offering Of $450 Million Of Convertible Senior Notes Due 2025  2020/02/26 13:05:00 Benzinga Feeds
SAN DIEGO , Feb. 26, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA ) announced today that it intends to offer (the "Offering"), subject to market and other considerations, $450,000,000 aggregate principal amount of Convertible Senior Notes due 2025 (the "Convertible Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). NuVasive also intends to grant to the initial purchasers of the Convertible Notes a 13-day option to purchase up to an additional $50,000,000 aggregate principal amount of the Convertible Notes. The Convertible Notes will be general unsecured obligations of NuVasive and interest will be paid semiannually in arrears on March 15 and September 15 of each year, beginning on September 15, 2020. The Convertible Notes will mature on March 15, 2025, unless earlier repurchased, redeemed or converted. Prior to the close of business on the business day immediately preceding September 15, 2024 , the Convertible Notes will be convertible at the option of holders only upon the satisfaction of certain conditions and during certain periods.
   NuVasive EPS beats by $0.09, beats on revenue  2020/02/20 21:03:26 Seeking Alpha
NuVasive (NASDAQ:NUVA): Q4 Non-GAAP EPS of $0.73 beats by $0.09; GAAP EPS of $0.55 beats by $0.21. Revenue of $310.35M (+7.6% Y/Y) beats by $5.42M. Press R

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 ニュ―ベイシブ NUVA NuVasive Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)